SMT. HANSA MEHTA LIB

List of Figures

Sr. No	Figure No	Title	Page No
1	1.1	Variation in drug plasmatic concentration with time following conventional administration and controlled release devices.	9
2	1.2	Schematic representation of membrane release systems.	13
3	1.3	Schematic representation of matrix release systems.	15
4	1.4	Schematic representation of degradable matrix systems.	15
5	1.5	Schematic representation of bioerodible crosslinked matrix.	16
6	1.6	Schematic representation of water insoluble/soluble matrix.	17
7	1.7	Schematic representation of bioerodible/biodegradable matrix.	17
8	1.8	Schematic representation of unilamellar liposomes.	21
9	1.9	Comparison of the structure of nanospheres and nanocapsules.	23
10	1.10	Schematic representation of dialysis procedure.	36
11	1.11	Schematic representation of diblock copolymer self assembly.	37

12	2.1	FTIR spectra of (A) lamotrigine (B) copolymeric nanoparticles and (C) lamotrigine loaded copolymeric nanoparticles.	60
13	2.2	Representative ^{1}H NMR spectra of (A) EMA homopolymer and (B) EMA: HEMA (70:30) copolymer.	72
14	2.3	Fineman-Ross method.	74
15	2.4	Inverted Fineman-Ross method.	75
16	2.5	Kelan –Tudos method.	76
17	2.6	Tidwell-Mortimer nonlinear least square method.	78
18	2.7	Effect of copolymer composition on molecular weight distribution by GPC.	80
19	2.8	Particle size distribution of poly (EMA: HEMA) copolymeric nanoparticles by dynamic light scattering. (A) 90:10, (B) 80:20, (C) 70:30, (D) 60:40, and (E) 50:50 EMA: HEMA.	82
20	2.9	TEM images of copolymeric nanoparticles (A) 90:10 poly (EMA: HEMA), (B) 50:50 poly (EMA: HEMA) and (C) lamotrigine loaded 90:10 poly (EMA: HEMA)	85
21	2.10	UV spectra of (a) lamotrigine, (b) copolymeric nanoparticles and (c) lamotrigine loaded copolymeric	87

		nanoparticles.	
22	2.11	Equilibrium swelling study of copolymeric nanoparticles in 0.1 N HCl. (O) 90:10 (EMA: HEMA), (□) 80:20 (EMA: HEMA), (Δ) 70:30 (EMA: HEMA), (●) 60:40 (EMA: HEMA), and (■) 50:50 (EMA: HEMA).	90
23	2.12	Percentage cumulative release pattern of lamotrigine through copolymer nanoparticles. (O) 90:10 (EMA: HEMA), (□) 80:20 (EMA: HEMA), (Δ) 70:30 (EMA: HEMA), (●) 60:40 (EMA: HEMA), and (■) 50:50 (EMA: HEMA).	92
24	2.13	Percentage drug retention at (A) 2-8 °C and (B) 30 °C from copolymeric nanoparticles with time. (O) 90:10 (EMA: HEMA), (□) 80:20 (EMA: HEMA), (Δ) 70:30 (EMA:HEMA), (●) 60:40 (EMA: HEMA), and (■) 50:50 (EMA: HEMA).	96
25	3.1	FTIR spectra of (A) poly (MMA-VCL) copolymer, (B) etoposide and (C) etoposide loaded copolymeric nanoparticles.	112
26	3.2	^{1}H NMR spectra of PMMA and poly (MMA-VCL) copolymer.	114
27	3.3	Fineman-Ross method.	115

28	3.4	Inverted Fineman-Ross method.	115
29	3.5	Tidwell-Mortimer nonlinear least square method.	116
30	3.6	Effect of copolymer composition on molecular weight distribution by GPC.	118
31	3.7	Effect of etoposide on molecular weight distribution of copolymer by GPC.	120
32	3.8	Percentage transmittance at 500 nm of aqueous solution containing a 0.1 mg/mL poly (MMA-co-VCL) solution at different temperatures. (o) 80:20 (MMA: VCL), (□) 60:40 (MMA: VCL), (Δ) 40:60 (MMA: VCL).	121
33	3.9	DSC thermograms of (A) etoposide (B) lyophilized copolymeric nanoparticles, (C) physical mixture of etoposide and copolymeric nanoparticles and (D) etoposide loaded copolymeric nanoparticles.	123
34	3.10	X-ray diffraction patterns of (A) etoposide, (B) copolymer nanoparticles and (C) etoposide loaded copolymeric nanoparticles.	124
35	3.11	Representative DLS histogram of poly (MMA-co-VCL) copolymer systems (A) (90:10) MMA-co-VCL, (B) (80:20) MMA-co-VCL, (C) (70:30) MMA-co-VCL, (D) (60:40) MMA-co-VCL, (E) (50:50) MMA-co-VCL, (F) (40:60) MMA-co-VCL.	126

36	3.12	Representative DLS histogram of etoposide loaded copolymeric nanoparticles (A) PMMA, (B) 75:25 poly (MMA-co- VCL), (C) 50:50 poly (MMA-co-VCL) and (D) 25:75 poly (MMA-co-VCL).	128
37	3.13	TEM images of (A) (50:50) poly (MMA-co-VCL) and (B) etoposide loaded (50:50) poly (MMA-co-VCL) copolymer system.	131
38	3.14	UV spectra of (A) etoposide (B) copolymeric nanoparticles and (C_{1-4}) etoposide loaded copolymeric nanoparticles.	132
39	3.15	Percentage cumulative release pattern of etoposide through copolymeric nanoparticles. (●) PMMA, (Δ) (75:25) MMA-co-VCL, (□) (50:50) MMA-co-VCL, (O) 25:75 (MMA-co-VCL).	133
40	3.16	Cytotoxicity profile of poly (MMA-co-VCL) nanoparticles of different compositions and SDS as a control, tested in B16F10 cell lines.	135
41	3.17	Cytotoxicity profile of etoposide loaded poly (MMA-co-VCL) nanoparticles of different compositions and etoposide as a control, tested in B16F10 cell lines.	137
42	4.1	Molecular structure of (A) venlafaxine hydrochloride, (B) sodium tripolyphosphate and (C) chitosan.	157

43	4.2	Effect of chitosan concentration on (■) particle size and (□) zeta potential at CS/TPP mass ratio 5:1 and pH = 5.	159
44	4.3	Effect of CS/TPP mass ratio on (■) particle size and (□) zeta potential at CS concentration = 1.5 mg/ml, TPP concentration = 0.5 mg/ml.	160
45	4.4	Effect of venlafaxine hydrochloride concentration on encapsulation efficiency (CS/TPP mass ratio 5:1, pH= 5).	162
46	4.5	Effect of venlafaxine hydrochloride concentration on (■) particle size and (□) zeta potential. (CS/TPP mass ratio 5:1, pH= 5).	162
47	4.6	Effect of chitosan concentration on encapsulation efficiency at CS/TPP mass ratio 5:1 and pH = 5.	163
48	4.7	Effect of CS/TPP mass ratio on encapsulation efficiency at chitosan and drug concentration 1.5 mg/ml and 0.6 mg/ml respectively at pH = 5.	163
49	4.8	Effect of PEG concentrations on (■) particle size and (□) zeta potential. (CS/TPP mass ratio = 5:1, venlafaxine hydrochloride concentration = 0.6 mg/ml, at pH = 5).	165
50	4.9	Effect of PEG concentration on encapsulation efficiency of venlafaxine hydrochloride in CS/TPP nanoparticles. (CS/TPP mass ratio = 5:1, venlafaxine hydrochloride concentration = 0.6 mg/ml,and pH = 5).	165

51	4.10	FTIR spectra of (A) CS/TPP nanoparticles, (B) chitosan, (C) venlafaxine hydrochloride loaded CS/TPP nanoparticles, (D) venlafaxine hydrochloride and (E) PEG coated CS/TPP nanoparticles.	167
52	4.11	DSC thermograms of (A) CS/TPP nanoparticles, (B) venlafaxine hydrochloride, (C) venlafaxine hydrochloride loaded CS/TPP nanoparticles, (D) physical mixture of venlafaxine hydrochloride and CS/TPP nanoparticles and (E) placebo PEG coated CS/TPP nanoparticles.	169
53	4.12	XRD patterns of (A) venlafaxine hydrochloride, (B) chitosan, (C) CS/TPP nanoparticles and (D) venlafaxine hydrochloride loaded CS/TPP nanoparticles.	171
54	4.13	XRD patterns of chitosan, PEG and PEG coated CS/TPP nanoparticles.	171
55	4.14	TEM images of (A) CS/TPP nanoparticles, (B) venlafaxine hydrochloride loaded CS/TPP nanoparticles and (C, D) PEG coated CS/TPP nanoparticles synthesized at CS/TPP mass ratio = 5:1, venlafaxine hydrochloride = 0.6 mg/ml, PEG = 30 mg/ml at pH = 5.	176
56	4.15	XPS analysis of CS, PEG, CS/TPP and PEG coated CS/TPP nanoparticles. (A) High resolution C (1S) photoelectron line showing carbon functionalities and	179

		relative composition in CS, PEG and PEG coated CS nanoparticles, (B) XPS Survey scan of CS/TPP nanoparticles and PEG coated CS/TPP nanoparticles.	
57	4.16	In-vitro release profile of venlafaxine hydrochloride from CS/TPP nanoparticles.	182